Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02733484
Other study ID # PTD02
Secondary ID
Status Recruiting
Phase N/A
First received April 5, 2016
Last updated March 9, 2017
Start date October 2015
Est. completion date December 2017

Study information

Verified date March 2017
Source Shanghai 10th People's Hospital
Contact Cuiling Zhu, MD
Phone 18817951953
Email 1263856671@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the probiotics will be effective in the treatment of obesity


Description:

This study aims to evaluate the effect of probiotics on the improvement of glucose and lipid metabolism, as well as the gut microbiota.Baseline, 1 month and 3 months data will be collected and put into analysis to provide some suggestions on the probiotics use in the clinical practice for obesity patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 15 Years to 60 Years
Eligibility Inclusion Criteria:

1. Age 15-60 years

2. BMI=28.0kg/m2

3. Agree to cooperate in the trial

4. Provision of written informed consent

Exclusion Criteria:

1. With chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance

2. Diabetes

3. Use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, H2 Blockers, proton pump inhibitors, corticosteroids or sex hormones

4. Use any probiotics in the last 3 months

5. Allergic constitution

6. Participating in any other clinical trials

7. Was not able to insist until the end

8. Pregnant and lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotics
the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
Placebo
the patients in this arm will receive placebo intervention

Locations

Country Name City State
China Shanghai 10th People's Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai 10th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary change from baseline in fasting blood-glucose at 1 month change of the fasting blood-glucose will be calculated at 1 month in comparison with the baseline 1 month
Primary change from baseline in fasting blood-glucose at 3 months change of the fasting blood-glucose will be calculated at 3 months in comparison with the baseline 3 months
Primary change from baseline in glycosylated hemoglobin change at 1 month change of the glycosylated hemoglobin will be calculated at 1 month in comparison with the baseline 1 month
Primary change from baseline in glycosylated hemoglobin change at 3 months change of the glycosylated hemoglobin will be calculated at 3 months in comparison with the baseline 3 months
Secondary change from baseline in gut microbiota at 1 month study the microbiota change of stool samples at 1 month in comparison with the baseline 1 month
Secondary change from baseline in gut microbiota at 3 months study the microbiota change of stool samples at 3 months in comparison with the baseline 3 months
Secondary change from baseline in triglyceride at 1 month 1 month
Secondary change from baseline in triglyceride at 3 months 3 months
Secondary change from baseline in cholesterol at 1 month 1 month
Secondary change from baseline in cholesterol at 3 months 3 months
Secondary change from baseline in high-density lipoprotein at 1 month 1 month
Secondary change from baseline in high-density lipoprotein at 3 months 3 months
Secondary change from baseline in low-density lipoprotein at 1 month 1 month
Secondary change from baseline in low-density lipoprotein at 3 months 3 months
Secondary change from baseline in glutamic oxalacetic transaminase at 1 month 1 month
Secondary change from baseline in glutamic oxalacetic transaminase at 3 months 3 months
Secondary change from baseline in alkaline transaminase at 1 month 1 month
Secondary change from baseline in alkaline transaminase at 3 months 3 months
Secondary change from baseline in alkaline phosphatase at 1 month 1 month
Secondary change from baseline in alkaline phosphatase at 3 months 3 months
Secondary change from baseline in superoxide dismutase at 1 month 1 month
Secondary change from baseline in superoxide dismutase at 3 months 3 months
Secondary change from baseline in C-reactive protein at 1 month 1 month
Secondary change from baseline in C-reactive protein at 3 months 3 months
Secondary change from baseline in uric acid at 1 month 1 month
Secondary change from baseline in uric acid at 3 months 3 months
Secondary change from baseline in tumor necrosis factor-a at 1 month 1 month
Secondary change from baseline in tumor necrosis factor-a at 3 months 3 months
Secondary change from baseline in interleukin-6 at 1 month 1 month
Secondary change from baseline in interleukin-6 at 3 months 3 months
Secondary change from baseline in interleukin-8 at 1 month 1 month
Secondary change from baseline in interleukin-8 at 3 months 3 months
Secondary change from baseline in fasting insulin at 1 month 1 month
Secondary change from baseline in fasting insulin at 3 months 3 months
Secondary change from baseline in c peptide at 1 month 1 month
Secondary change from baseline in c peptide at 3 months 3 months
Secondary change from baseline in visceral fat fraction at 1 month 1 month
Secondary change from baseline in visceral fat fraction at 3 months 3 months
Secondary change from baseline in body age at 1 month 1 month
Secondary change from baseline in body age at 3 months 3 months
Secondary change from baseline in percentage of body fat at 1 month 1 month
Secondary change from baseline in percentage of body fat at 3 months 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2